stockportfolio.pro
Stocks / OMCL vs VRDN
OMCL vs VRDN
Omnicell, Inc. and Viridian Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Omnicell, Inc. (OMCL) | Viridian Therapeutics, Inc. (VRDN) | |
|---|---|---|
| Market cap | $1.7B | $1.8B |
| Revenue (latest FY) | $1.18B | $70.85M |
| Net income (latest FY) | $2.05M | $-342.60M |
| Revenue growth (5y CAGR) | 5.8% | 132.2% |
| Net margin | 0.2% | -483.6% |
| Return on equity | 0.2% | -47.4% |
| P/E ratio | 87.3 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open OMCL — free Open VRDN — freeFrequently asked questions
Which is bigger, OMCL or VRDN?
Viridian Therapeutics, Inc. is larger by market capitalization — $1.8B versus $1.7B.
Which grows faster, OMCL or VRDN?
Over the last five fiscal years, Viridian Therapeutics, Inc. grew revenue faster — 132.2%/yr versus 5.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.